{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:05:03Z","timestamp":1760853903214},"reference-count":9,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.remn.2016.08.001","type":"journal-article","created":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T13:30:46Z","timestamp":1477402246000},"page":"116-119","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Uso del 177Lu-DOTATATE como terapia en carcinomas de tiroides yodorrefractarios"],"prefix":"10.1016","volume":"36","author":[{"given":"P.","family":"Oliv\u00e1n-Sasot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Falg\u00e1s-Lacueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Garc\u00eda-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Vera-Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Olivas-Arroyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bello-Arques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remn.2016.08.001_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid."},{"key":"10.1016\/j.remn.2016.08.001_bib0055","first-page":"3228","article-title":"Expression of the Na+\/I- symporter gene in human thyroid tumors: A comparison study with other thyroid-specific genes","volume":"84","author":"Lazar","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.remn.2016.08.001_bib0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.semnuclmed.2010.10.002","article-title":"The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: The TENIS syndrome","volume":"41","author":"Silberstein","year":"2011","journal-title":"Semin Nucl Med."},{"key":"10.1016\/j.remn.2016.08.001_bib0065","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.endonu.2015.08.007","article-title":"Spanish consensus for the management of patients with advanced radioactive iodine refractory differentiated thyroid cancer","volume":"63","author":"Riesco-Eizaguirre","year":"2016","journal-title":"Endocrinol Nutr."},{"key":"10.1016\/j.remn.2016.08.001_bib0070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-0029-1243636","article-title":"Somatostatin receptor subtype expression in human thyroid tumours","volume":"42","author":"Klagge","year":"2010","journal-title":"Horm Metab Res."},{"key":"10.1016\/j.remn.2016.08.001_bib0075","first-page":"39","article-title":"Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: Toxicity, response and survival analysis","volume":"4","author":"Budiawan","year":"2013","journal-title":"Am J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remn.2016.08.001_bib0080","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Bodei","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remn.2016.08.001_bib0085","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00005-014-0318-6","article-title":"Peptide receptor radionuclide therapy of differentiated thyroid cancer: Efficacy and toxicity","volume":"63","author":"Czepczy\u0144ski","year":"2015","journal-title":"Arch Immunol Ther Exp (Warsz)."},{"key":"10.1016\/j.remn.2016.08.001_bib0090","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/cncr.24272","article-title":"[90Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer","volume":"115","author":"Iten","year":"2009","journal-title":"Cancer."}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X16301366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X16301366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T08:26:04Z","timestamp":1536308764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253654X16301366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S2253654X16301366"],"URL":"https:\/\/doi.org\/10.1016\/j.remn.2016.08.001","relation":{},"ISSN":["2253-654X"],"issn-type":[{"value":"2253-654X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uso del 177Lu-DOTATATE como terapia en carcinomas de tiroides yodorrefractarios","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2016.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Espa\u00f1a, S.L.U. y SEMNIM. All rights reserved.","name":"copyright","label":"Copyright"}]}}